Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma.
Saved in:
| Title: | Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma. |
|---|---|
| Authors: | Shah B; Moffitt Cancer Center, Tampa, FL, USA., Challagulla S; BeOne Medicines, San Carlos, CA, USA., Xu S; BeOne Medicines Ltd, Shanghai, China., Williams R; BeOne Medicines, San Carlos, CA, USA., Ren S; ConnectHEOR Ltd, London, UK.; SCHARR, University of Sheffield, Sheffield, UK., Srivastava T; ConnectHEOR Ltd, London, UK., Gautam R; ConnectHEOR Ltd, London, UK., Yang K; BeOne Medicines, San Carlos, CA, USA., Saba NS; Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, LA, USA., Tam CS; Alfred Hospital and Monash University, Melbourne, Victoria, Australia. |
| Source: | Leukemia & lymphoma [Leuk Lymphoma] 2025 Dec; Vol. 66 (12), pp. 2238-2248. Date of Electronic Publication: 2025 Sep 01. |
| Publication Type: | Journal Article; Comparative Study |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1029-2403 |
|---|---|
| DOI: | 10.1080/10428194.2025.2541911 |
